By Tapan Panchal

LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration has approved the usage of Brilinta tablets at a new 60 milligram dose on patients with a history of heart attack beyond the first year.

The company said the new Brilinta 60 milligrams tablet is expected to be available in pharmacies by the end of September. Brilinta was first approved by the FDA in July 2011.

-Write to Tapan Panchal at tapan.panchal@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

September 04, 2015 02:33 ET (06:33 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.